Reconnaissance Soil Geochemical Survey of Gibraltar

Liesl Mesilio,M. Farago,I. Thornton

DOI: https://doi.org/10.1023/A:1021232412519

2003-03-01

Environmental Geochemistry and Health

Abstract:

What problem does this paper attempt to address?

Gonorrhea in the female.

M. Parker

Abstract:
Hemorrhagic and ischemic stroke in patients with coronavirus disease 2019: incidence, risk factors, and pathogenesis - a systematic review and meta-analysis

Syahrul Syahrul,Helnida Anggun Maliga,Muhammad Ilmawan,Marhami Fahriani,Sukamto S. Mamada,Jonny Karunia Fajar,Andri Frediansyah,Faza Nabila Syahrul,Imran Imran,Salim Haris,Aldy Safruddin Rambe,Talha Bin Emran,Ali A. Rabaan,Ruchi Tiwari,Kuldeep Dhama,Firzan Nainu,Endang Mutiawati,Harapan Harapan

DOI: https://doi.org/10.12688/f1000research.42308.1

2021-01-19

F1000Research

Abstract:Background : In this study, we aimed to determine the global prevalence, chronological order of symptom appearance, and mortality rates with regard to hemorrhagic and ischemic stroke in patients with coronavirus disease 2019 (COVID-19) and to discuss possible pathogeneses of hemorrhagic and ischemic stroke in individuals with the disease. Methods : We searched the PubMed, Scopus, and Web of Science databases for relevant articles published up to November 8, 2020. Data regarding study characteristics, hemorrhagic stroke, ischemic stroke, and COVID-19 were retrieved in accordance with the PRISMA guidelines. The Newcastle-Ottawa scale was used to assess the quality of the eligible studies. The pooled prevalence and mortality rate of hemorrhagic and ischemic stroke were calculated. Results : The pooled estimate of prevalence of hemorrhagic stroke was 0.46% (95% CI 0.40%–0.53%; I 2 =89.81%) among 67,155 COVID-19 patients and that of ischemic stroke was 1.11% (95% CI 1.03%–1.22%; I 2 =94.07%) among 58,104 COVID-19 patients. Ischemic stroke was more predominant (incidence: 71.58%) than hemorrhagic stroke (incidence: 28.42%) in COVID-19 patients who experienced a stroke. In COVID-19 patients who experienced a stroke, hospital admission with respiratory symptoms was more commonly reported than that with neurological symptoms (20.83% for hemorrhagic stroke and 5.51% for ischemic stroke versus 6.94% for hemorrhagic stroke and 5.33% for ischemic stroke, respectively). The pooled mortality rate of COVID-19 patients who experienced a hemorrhagic and ischemic stroke was 44.72% (95% CI 36.73%–52.98%) and 36.23% (95% CI 30.63%–42.24%), respectively. Conclusions : Although the occurrence of hemorrhagic and ischemic stroke is low, the mortality rates of both stroke types in patients with COVID-19 are concerning, and therefore, despite several potential pathogeneses that have been proposed, studies aimed at definitively elucidating the mechanisms of hemorrhagic and ischemic stroke in individuals with COVID-19 are warranted. PROSPERO registration: CRD42020224470 (04/12/20)
Incidence of Stroke in Randomized Trials of COVID-19 Therapeutics: A Systematic Review and Meta-Analysis.

Sanjana Nagraj,Dimitrios Varrias,Gabriel Hernandez Romero,Heitor T. Santos,Dimitrios Karamanis,Dimitrios Sagris,Eleni Korompoki,Haralampos Milionis,Leonidas Palaiodimos,George Ntaios

DOI: https://doi.org/10.1161/STROKEAHA.122.040233

IF: 10.17

2022-08-25

Stroke

Abstract:COVID-19 has been frequently associated with an increased risk of thrombotic complications. There have also been reports of an increased likelihood of stroke, although its true incidence in patients with COVID-19 is currently unknown. Electronic databases PubMed and Scopus were searched from inception up to July 30, 2021 to identify randomized controlled studies in patients with confirmed COVID-19 undergoing one or more interventions. Studies were screened for eligibility using a predefined inclusion criterion and selected using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A random-effects model meta-analysis was conducted, and heterogeneity was assessed using I-squared test. Out of 3960 potentially eligible articles, 77 randomized studies (38 732 patients) were included. Mean age of the study population was 55±9.3 years. Females constituted 38% of the study population and mean duration of follow-up after study enrollment was 23±12.9 days. Cumulative incidence of stroke in the overall study population was 0.001 (95% CI, 0.001–0.002) with a total of 65 events in 38 732 patients, corresponding to an absolute incidence of 0.168%. Incidence of stroke in the inpatient population was 0.001 (95% CI, 0.001–0.002; 65 events in 37 069 patients), corresponding to an absolute incidence of 0.175%. No strokes were observed in the outpatient setting. The overall incidence of stroke in patients with COVID-19 appears to be lower than that reported in previous observational reports. Download figure Download PowerPoint

peripheral vascular disease,clinical neurology
Abstract P81: SARS-CoV-2 and Stroke Characteristics a Report From the Multinational COVID-19 Stroke Study Group

Shima Shahjouei,Georgios K Tsivgoulis,Ghasem Farahmand,Eric Koza,Ashkan Mowla,Stefania Mondello,Achille Cernigliaro,Anna Ranta,Martin Punter,Soheil Naderi,Durgesh Chaudhary,Venkatesh Avula,Jiang Li,vida abedi,Ramin Zand,

DOI: https://doi.org/10.1161/str.52.suppl_1.p81

IF: 10.17

2021-03-01

Stroke

Abstract:Objective and Design: We conducted a multinational observational study on features of consecutive acute ischemic stroke (AIS), intracranial hemorrhage (ICH), and cerebral venous or sinus thrombosis (CVST) among SARS-CoV-2 infected patients. Main Outcome Measures: We investigated the association of demographics, clinical data, geographical regions, and countries’ health expenditure among AIS patients with the risk of large vessel occlusion (LVO), stroke severity as measured by National Institute of Health stroke scale (NIHSS), and stroke subtype as measured by the TOAST criteria. Additionally, we applied unsupervised machine learning algorithms to uncover possible similarities among stroke patients. Results: Among the 136 tertiary centers of 32 countries who participated in this study, 71 centers from 17 countries had at least one eligible stroke patient. Out of 432 patients included, 323(74.8%) had AIS, 91(21.1%) ICH, and 18(4.2%) CVST. Among 23 patients with subarachnoid hemorrhage, 16(69.5%) had no evidence of aneurysm. A total of 183(42.4%) patients were women, 104(24.1%) patients were younger than 55 years, and 105(24.4%) patients had no identifiable vascular risk factors. Among 380 patients who had known interval onset of the SARS-CoV-2 and stroke, 144(37.8%) presented to the hospital with chief complaints of stroke-related symptoms, with asymptomatic or undiagnosed SARS-CoV-2 infection. Among AIS patients 44.5% had LVO; 10% had small artery occlusion according to the TOAST criteria. We observed a lower median NIHSS (8[3-17], versus 11[5-17]; p=0.02) and higher rate of mechanical thrombectomy (12.4% versus 2%; p<0.001) in countries with middle to high-health expenditure when compared to countries with lower health expenditure. The unsupervised machine learning identified 4 subgroups, with a relatively large group with no or limited comorbidities. Conclusions and Relevance: We observed a relatively high number of young, and asymptomatic SARS-CoV-2 infections among stroke patients. Traditional vascular risk factors were absent among a relatively large cohort of patients. The stroke severity was lower and rate of mechanical thrombectomy was higher among countries with middle to high-health expenditure.

peripheral vascular disease,clinical neurology
Acute Ischemic Stroke and COVID-19: An Analysis of 27 676 Patients.

Adnan I. Qureshi,William I. Baskett,Wei Huang,Daniel Shyu,Danny Myers,Murugesan Raju,Iryna Lobanova,M. Fareed K. Suri,S. Hasan Naqvi,Brandi R. French,Farhan Siddiq,Camilo R. Gomez,Chi-Ren Shyu

DOI: https://doi.org/10.1161/strokeaha.120.031786

IF: 10.17

2021-02-06

Stroke

Abstract:Acute ischemic stroke may occur in patients with coronavirus disease 2019 (COVID-19), but risk factors, in-hospital events, and outcomes are not well studied in large cohorts. We identified risk factors, comorbidities, and outcomes in patients with COVID-19 with or without acute ischemic stroke and compared with patients without COVID-19 and acute ischemic stroke. We analyzed the data from 54 health care facilities using the Cerner deidentified COVID-19 dataset. The dataset included patients with an emergency department or inpatient encounter with discharge diagnoses codes that could be associated to suspicion of or exposure to COVID-19 or confirmed COVID-19. A total of 103 (1.3%) patients developed acute ischemic stroke among 8163 patients with COVID-19. Among all patients with COVID-19, the proportion of patients with hypertension, diabetes, hyperlipidemia, atrial fibrillation, and congestive heart failure was significantly higher among those with acute ischemic stroke. Acute ischemic stroke was associated with discharge to destination other than home or death (relative risk, 2.1 [95% CI, 1.6–2.4]; P <0.0001) after adjusting for potential confounders. A total of 199 (1.0%) patients developed acute ischemic stroke among 19 513 patients without COVID-19. Among all ischemic stroke patients, COVID-19 was associated with discharge to destination other than home or death (relative risk, 1.2 [95% CI, 1.0–1.3]; P =0.03) after adjusting for potential confounders. Acute ischemic stroke was infrequent in patients with COVID-19 and usually occurs in the presence of other cardiovascular risk factors. The risk of discharge to destination other than home or death increased 2-fold with occurrence of acute ischemic stroke in patients with COVID-19. Download figure Download PowerPoint

peripheral vascular disease,clinical neurology
COVID-19 and cerebrovascular diseases: a comprehensive overview

Georgios Tsivgoulis,Lina Palaiodimou,Ramin Zand,Vasileios Arsenios Lioutas,Christos Krogias,Aristeidis H. Katsanos,Ashkan Shoamanesh,Vijay K. Sharma,Shima Shahjouei,Claudio Baracchini,Charalambos Vlachopoulos,Rossetos Gournellis,Petros P. Sfikakis,Else Charlotte Sandset,Andrei V. Alexandrov,Sotirios Tsiodras

DOI: https://doi.org/10.1177/1756286420978004

2020-01-01

Therapeutic Advances in Neurological Disorders

Abstract:Neurological manifestations are not uncommon during infection with the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A clear association has been reported between cerebrovascular disease and coronavirus disease 2019 (COVID-19). However, whether this association is causal or incidental is still unknown. In this narrative review, we sought to present the possible pathophysiological mechanisms linking COVID-19 and cerebrovascular disease, describe the stroke syndromes and their prognosis and discuss several clinical, radiological, and laboratory characteristics that may aid in the prompt recognition of cerebrovascular disease during COVID-19. A systematic literature search was conducted, and relevant information was abstracted. Angiotensin-converting enzyme-2 receptor dysregulation, uncontrollable immune reaction and inflammation, coagulopathy, COVID-19-associated cardiac injury with subsequent cardio-embolism, complications due to critical illness and prolonged hospitalization can all contribute as potential etiopathogenic mechanisms leading to diverse cerebrovascular clinical manifestations. Acute ischemic stroke, intracerebral hemorrhage, and cerebral venous sinus thrombosis have been described in case reports and cohorts of COVID-19 patients with a prevalence ranging between 0.5% and 5%. SARS-CoV-2-positive stroke patients have higher mortality rates, worse functional outcomes at discharge and longer duration of hospitalization as compared with SARS-CoV-2-negative stroke patients in different cohort studies. Specific demographic, clinical, laboratory and radiological characteristics may be used as ‘red flags’ to alarm clinicians in recognizing COVID-19-related stroke.

clinical neurology
Influence of ascending versus descending balloon counterpulsation on bypass graft blood flow.

R. Gitter,Chris M. Cate,Kenneth Smart,G. Jett

DOI: https://doi.org/10.1016/S0003-4975(97)01296-4

1998-02-01

Abstract:
Risk of stroke in hospitalized SARS-CoV-2 infected patients: A multinational study

Shima Shahjouei,Soheil Naderi,Jiang Li,Ayesha Khan,Durgesh Chaudhary,Ghasem Farahmand,Shailesh Male,Christoph Griessenauer,Mirna Sabra,Stefania Mondello,Achille Cernigliaro,Faezeh Khodadadi,Apoorva Dev,Nitin Goyal,Sakineh Ranji-Burachaloo,Oluwaseyi Olulana,Venkatesh Avula,Seyed Amir Ebrahimzadeh,Orkhan Alizada,Mehmet Murat Hancı,Askar Ghorbani,Alaleh Vaghefi far,Annemarei Ranta,Martin Punter,Mahtab Ramezani,Nima Ostadrahimi,Georgios Tsivgoulis,Paraskevi C. Fragkou,Peyman Nowrouzi-Sohrabi,Emmanouil Karofylakis,Sotirios Tsiodras,Saeideh Neshin Aghayari Sheikh,Alia Saberi,Mika Niemelä,Behnam Rezai Jahromi,Ashkan Mowla,Mahsa Mashayekhi,Reza Bavarsad Shahripour,Seyed Aidin Sajedi,Mohammad Ghorbani,Arash Kia,Nasrin Rahimian,Vida Abedi,Ramin Zand

DOI: https://doi.org/10.1016/j.ebiom.2020.102939

IF: 11.205

2020-09-01

EBioMedicine

Abstract:BACKGROUND: There is an increased attention to stroke following SARS-CoV-2. The goal of this study was to better depict the short-term risk of stroke and its associated factors among SARS-CoV-2 hospitalized patients.METHODS: This multicentre, multinational observational study includes hospitalized SARS-CoV-2 patients from North and South America (United States, Canada, and Brazil), Europe (Greece, Italy, Finland, and Turkey), Asia (Lebanon, Iran, and India), and Oceania (New Zealand). The outcome was the risk of subsequent stroke. Centres were included by non-probability sampling. The counts and clinical characteristics including laboratory findings and imaging of the patients with and without a subsequent stroke were recorded according to a predefined protocol. Quality, risk of bias, and heterogeneity assessments were conducted according to ROBINS-E and Cochrane Q-test. The risk of subsequent stroke was estimated through meta-analyses with random effect models. Bivariate logistic regression was used to determine the parameters with predictive outcome value. The study was reported according to the STROBE, MOOSE, and EQUATOR guidelines.FINDINGS: We received data from 26,175 hospitalized SARS-CoV-2 patients from 99 tertiary centres in 65 regions of 11 countries until May 1st, 2020. A total of 17,799 patients were included in meta-analyses. Among them, 156(0.9%) patients had a stroke-123(79%) ischaemic stroke, 27(17%) intracerebral/subarachnoid hemorrhage, and 6(4%) cerebral sinus thrombosis. Subsequent stroke risks calculated with meta-analyses, under low to moderate heterogeneity, were 0.5% among all centres in all countries, and 0.7% among countries with higher health expenditures. The need for mechanical ventilation (OR: 1.9, 95% CI:1.1-3.5, p = 0.03) and the presence of ischaemic heart disease (OR: 2.5, 95% CI:1.4-4.7, p = 0.006) were predictive of stroke.INTERPRETATION: The results of this multi-national study on hospitalized patients with SARS-CoV-2 infection indicated an overall stroke risk of 0.5%(pooled risk: 0.9%). The need for mechanical ventilation and the history of ischaemic heart disease are the independent predictors of stroke among SARS-CoV-2 patients.FUNDING: None.

medicine, research & experimental
Abstract P88: Risk of Stroke in Hospitalized SARS-Cov-2 Infected Patients a Multinational Population-Based Study

Shima Shahjouei,Soheil Naderi,Jiang Li,Durgesh Chaudhary,Christoph Griessenauer,Ghasem Farahmand,Stefania Mondello,Achille Cernigliaro,Faezeh Khodadadi,Venkatesh Avula,Anna Ranta,Martin Punter,Georgios K Tsivgoulis,Ashkan Mowla,vida abedi,Ramin Zand,,

DOI: https://doi.org/10.1161/str.52.suppl_1.p88

IF: 10.17

2021-03-01

Stroke

Abstract:The goal of this study was to better depict the short-term risk of stroke and its associated factors among SARS-CoV-2 hospitalized patients. Data Source: This multicenter, multinational observational study includes hospitalized SARS-CoV-2 patients from North and South America (United States, Canada, and Brazil), Europe (Greece, Italy, Finland, and Turkey), Asia (Lebanon, Iran, and India), and Oceania (New Zealand). Main Outcomes and Measures: The outcome was the risk of subsequent stroke (ischemic stroke, intracranial hemorrhage, cerebral venous/sinus thrombosis). The counts and clinical characteristics including laboratory findings and imaging of the patients with and without a subsequent stroke were recorded according to a predefined study protocol. Data Extraction and Synthesis: Quality, risk of bias, and heterogeneity assessments were conducted according to ROBINS-E and Cochrane Q-test. The risk of subsequent stroke was estimated through meta-analyses with random effect models. Binary logistic regression was used to determine the associated factors with the outcome measure. The study was reported according to the STROBE, MOOSE, and EQUATOR guidelines. Results: We received data from 18,311 hospitalized SARS-CoV-2 patients from 77 tertiary centers in 46 regions of 11 countries until May 1 st , 2020. A total of 17,799 patients were included in meta-analyses. Among them, 156(0.9%) patients had a stroke—123(79%) ischemic stroke, 27(17%) intracerebral/subarachnoid hemorrhage, and 6(4%) cerebral sinus thrombosis. Subsequent stroke risks calculated with meta-analyses, under low to moderate heterogeneity, were 0.5% among all centers in all countries, and 0.7% among countries with higher health expenditures. The need for mechanical ventilation (OR: 1.9, 95% CI:1.1-3.5, p = 0.03) and the presence of ischemic heart disease (OR: 2.5, 95% CI:1.4-4.7, p =0·006) were predictive of stroke. Conclusion and Relevance: The results of this multi-national study on hospitalized patients with SARS-CoV-2 infection indicated an overall stroke risk of 0.5% (pooled risk: 0.9%). The need for mechanical ventilation and the history of ischemic heart disease are the independent predictors of stroke among SARS-CoV-2 patients.

peripheral vascular disease,clinical neurology
An Electron Optical Survey of Iron Oxide o Films Produced in H 20 , 1 . 5 % LiOH , and ULiOT / EDTA ( pH 11 ) Solutions at 316 0 C

L. R.,M.

Abstract:In the exploration of steel corrosion mechanisms pertinent to steam power generation, Holl has been investigated as an alkalizing agent to form protective oxide films on Ioiler walls. Steel capsules treated in three different ways, (a) with H20, (b) with 1.5% UiOH solution, and (c) with LiOH/ EDITA rpl I I) at 316°(., formed films which, in ihe initial stages of development, were shown to be Fea( ). However, the crystallite size, the degree of orientation, and the film uniformity and continuity, determined by electron microscopy and diffraction, varied with the method and length of treatment. The fihln foirmed hy distilled water showed small (1000 to 2000 A), oriented crystals With sharply delineated areas of growth. When the l.iOH solotion was used in the treatnent, larger crystals were formed. but flaws were still noticeable after 24 hours. With the LiOH/EDTA solution, the growth of the crystals was very rapid, forming a thick. coherent film on the metal, which should offer excellent protection iagainst corrosion. INTRODUCTION series of tests, LiOH was found to be superior to In the course of exploraiion of stee corrosion NaOH in corrosion inhibition when these alkalies meh m pare used independently in solution with no other a ime n hanisms pertinent to steam power generation, additives. attention has recently been given to LiOH s an In connection with further studies of corrosion alkalizing medium for treatment of steel bt mechanisms in these systems, the techniques of elevatedl temperatures (1 ,2). LiOH cannot be electron microscopy and electron diffraction are simply substituted for NaOH in the conventional being utilized as an aid in the analysis of the Navy low-phosphate treatment for boiler water strutured of the go pc ss s of te primril becuseof postio ofL6P0 onthe structure and of the growth processes of protective primarily because of deposition of LibPOe on the films. These techniques have been used to examine boiler walls (3). Investigations have been underthe initial processes of oxide film formation in taken to evaluate LiOH boiler water treatments H20, 1.5% LiOH solution, and LiOH/EDTA where an organic chelating agent, ethylenedisolution at 316TC (conditions related to boiler aminetetraacetic acid (EDTA), is used instead of operation) to ascertain whether the morphology Jphosphate to prevent hard scale formation by the and/or composition of the surface oxide differed alkaline earth ions which are always present in systematically with the treatments and whether sea water distillate. Preliminary studies in capsuch differences, if found, could be correlated with stile systems at this laboratory and in model the relative degrees of corrosion inhibition preboilers at the Marine Engineering Laboratory have viously observed for these additive systems. indicated that this type of treatment is preferable from the standpoint of prevention of boiler wall corrosion to the low-phosphate control treatment EXPERIMEAN AL TECHNIQUES presently being used by the Navy (3). In the same AND EQUIPMENT SThree test solutions, prepared from distilled * NRI. Problem C05-22; Project RR 001.01-43-4758. This is an interim water and reagent grade chemicals, were used in report on one phase of the problem: work is continuing on the problem. te experiment (adistille wer only Manuscript submitted May 24, 1966. these experiments: (a) distilled water only,
Bihemispheric ischemic strokes in patients with COVID-19

Christeena Kurian,Stephan Mayer,Gurmeen Kaur,Ramandeep Sahni,Eric Feldstein,Mena Samaan,Divya Viswanathan,Tamarah Sami,Syed Faizan Ali,Hussein Al-Shammari,Jessica Bloomfield,Michelle Bravo,Rolla Nuoman,Edwin Gulko,Chirag D Gandhi,Fawaz Al-Mufti

DOI: https://doi.org/10.4103/bc.bc_65_21

2022-03-21

Abstract:Background: There is emerging evidence that COVID-19 can trigger thrombosis because of a hypercoagulable state, including large-vessel occlusion ischemic strokes. Bihemispheric ischemic stroke is uncommon and is thought to indicate an embolic source. Here, we examine the findings and outcomes of patients with bihemispheric stroke in the setting of COVID-19. Methods: We performed a retrospective cohort study at a quaternary academic medical center between March 1, 2020, and April 30, 2020. We identified all patients with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection who presented with simultaneous bihemispheric ischemic strokes. Results: Of 637 COVID-19 admissions during the 2-month period, 13 had a diagnosis of acute ischemic stroke, including 5 who developed bihemispheric cerebral infarction. Three of those 5 (60%) were female, median age was 54 (range 41-67), and all five were being managed for severe COVID-19-related pneumonia complicated by acute kidney injury and liver failure before the diagnosis of cerebral infarction was established. Five presented with elevated ferritin, lactate dehydrogenase, and interleukin-6 (IL-6) levels, and four had lymphopenia and elevated D-dimer levels. All patients underwent neuroimaging with computed tomography for persistent depressed mentation, with or without a focal neurologic deficit, demonstrating multifocal ischemic strokes with bihemispheric involvement. Outcome was poor in all patients: two were discharged to a rehabilitation facility with moderate-to-severe disability and three (60%) patients died. Conclusions: Stroke is implicated in SARS-CoV-2 infection. Although causality cannot be established, we present the imaging and clinical findings of patients with COVID-19 and simultaneous bihemispheric ischemic strokes. Multifocal ischemic strokes with bihemispheric involvement should be considered in COVID-19 patients with severe infection and poor neurologic status and may be associated with poor outcomes.
Efficacy and safety of recanalization therapy for acute ischemic stroke with COVID-19: A systematic review and meta-analysis

Zilan Wang,Haiying Teng,Xiaoxiao Wu,Xingyu Yang,Youjia Qiu,Huiru Chen,Zhouqing Chen,Zhong Wang,Gang Chen

DOI: https://doi.org/10.3389/fneur.2022.984135

IF: 3.4

2022-08-30

Frontiers in Neurology

Abstract:Background: The novel coronavirus disease 2019 (COVID-19) has rapidly spread worldwide and created a tremendous threat to global health. Growing evidence suggests that patients with COVID-19 have more severe acute ischemic stroke (AIS). However, the overall efficacy and safety of recanalization therapy for AIS patients infected by the SARS-CoV-2 virus is unknown. Methods: The PRISMA guideline 2020 was followed. Two independent investigators systematically searched databases and ClinicalTrials.gov to identify relevant studies published up to 31 March 2022. AIS patients who received any recanalization treatments were categorized into those with COVID-19 and those without COVID-19. The main efficacy outcomes were patients' functional independence on discharge and successful recanalization, and the safety outcomes were in-hospital mortality and symptomatic intracranial hemorrhage. Subgroup analyses were implemented to assess the influence of admission National Institutes of Health Stroke Scale and different recanalization treatments on the outcomes. STATA software 12.0 was used for the statistical analysis. Results: This systematic review and meta-analysis identified 10 studies with 7,042 patients, including 596 COVID-19 positive patients and 6,446 COVID-19 negative patients. Of the total patients, 2,414 received intravenous thrombolysis while 4,628 underwent endovascular thrombectomy. COVID-19 positive patients had significantly lower rates of functional independence at discharge [odds ratio (OR) 0.30, 95% confidence interval (CI) 0.15 to 0.59, P = 0.001], lower rates of successful recanalization (OR 0.40, 95% CI 0.24 to 0.68, P = 0.001), longer length of hospital stay (weighted mean difference 5.09, 95% CI 1.25 to 8.94, P = 0.009) and higher mortality rates (OR 3.38, 95% CI 2.43 to 4.70, P < 0.0001). Patients with COVID-19 had a higher risk of symptomatic intracranial hemorrhage than the control group, although the difference did not reach statistical significance (OR 2.34, 95% CI 0.99 to 5.54, P = 0.053). Conclusions: Compared with COVID-19 negative AIS patients who received recanalization treatments, COVID-19 positive patients turned out to have poorer outcomes. Particular attention needs to be paid to the treatments for these COVID-19 patients to decrease mortality and morbidity. Long-term follow-up is necessary to evaluate the recanalization treatments for AIS patients with COVID-19. Systematic review registration: https://inplasy.com/inplasy-2022-4-0022/, identifier: INPLASY202240022.

neurosciences,clinical neurology
Association between SARS-CoV-2 and Stroke: Perspectives from a metaumbrella-review.

Andreza Maria Luzia Baldo de Souza,Enoque Fernandes de Araújo,Antonio Carlos Pereira,Nelson Carvas Junior,Augusto César Raimundo,Marcelo de Castro Meneghim

DOI: https://doi.org/10.1101/2024.10.01.24314742

2024-10-03

Abstract:In the face of the global COVID-19 pandemic, the need arose to investigate potential complications associated with SARS-CoV-2, including the risk of Stroke. Objective: This study aimed to verify the association between SARS-CoV-2 and the risk of Stroke, based on systematic reviews and meta-analyses, in order to assess the inclusion of the virus as a new risk factor for cerebrovascular diseases. Methods: A metaumbrella was conducted, which included 34 systematic reviews, of which 4 were selected for the final analysis based on methodological quality and consistency. The analysis aggregated the results of 70 primary studies, considering different stroke subtypes and outcomes associated with COVID-19. Study heterogeneity was assessed using the I index, and significance bias was verified using Egger's test. Results: The analysis showed that the severity of COVID-19 is significantly associated with an increased risk of stroke (eOR = 2.48; 95%CI: 1.55 - 3.95), particularly for ischemic stroke (eOR = 1.76; 95%CI: 1.11 - 2.80) and hemorrhagic stroke (eOR = 3.86; 95%CI: 1.79 - 8.33). Additionally, patients with cerebrovascular comorbidities had higher mortality (eOR = 2.48; 95%CI: 2.48 - 19.63), as did those who had previously suffered a stroke (eOR = 6.08; 95%CI: 3.73 - 9.91). Conclusion: The association between SARS-CoV-2 and stroke was consistent and significant, suggesting that COVID-19 should be considered a new risk factor for cerebrovascular diseases. However, the high heterogeneity among the studies analyzed reinforces the need for further research to consolidate this relationship.

Public and Global Health
Risk of ischemic stroke in patients recovered from COVID-19 infection: A systematic review and meta-analysis

Marco Zuin,Maria Mazzitelli,Gianluca Rigatelli,Claudio Bilato,Anna Maria Cattelan

DOI: https://doi.org/10.1177/23969873231190432

IF: 6.1

2023-07-28

European Stroke Journal

Abstract:European Stroke Journal, Ahead of Print. Background:Data regarding the risk of ischemic stroke within 1 year after the post-acute phase of COVID-19 remain scant. We assess the risk of ischemic stroke in COVID-19 survivors after SARS-CoV-2 infection by performing a systematic review and meta-analysis of the available data.Methods:Following the PRISMA guidelines, we searched Medline and Scopus to locate all articles published up to February 11, 2023, reporting the risk of incident ischemic stroke in adult patients recovered from COVID-19 infection compared to non-infected patients (controls) defined as those who did not experience the infection over the same follow-up period. Ischemic stroke risk was evaluated using the Mantel–Haenszel random effects models with adjusted Hazard ratio (HR) as the effect measure with 95% confidence interval (CI) while heterogeneity was assessed using Higgins I2 statistic.Results:Overall, 23,559,428 patients (mean age 56, 1 year, 54.3% males), of whom 1,595,984 had COVID-19, were included. Over a mean follow-up of 9.2 months, ischemic stroke occurred in 4.40 [95% CI: 4.36–4.43] out of 1000 patients survived to COVID-19 compared to 3.25 [95% CI:3.21–3.29] out of 1000 controls. Recovered COVID-19 patients presented a higher risk of ischemic stroke ((HR: 2.06, 95% CI: 1.75–2.41, p < 0.0001, I2 = 63.7%) compared to people who did not have COVID-19. COVID-19 patients hospitalized at the time of the infection have a subsequent higher risk of stroke during the follow-up compared to those non-hospitalized.Conclusions:Recovered COVID-19 patients have a higher risk of ischemic stroke compared to subjects from the general population within 9 months from the index infection.
Stroke in SARS-CoV-2 Infection: A Pictorial Overview of the Pathoetiology

Saeideh Aghayari Sheikh Neshin,Shima Shahjouei,Eric Koza,Isabel Friedenberg,Faezeh Khodadadi,Mirna Sabra,Firas Kobeissy,Saeed Ansari,Georgios Tsivgoulis,Jiang Li,Vida Abedi,Donna M. Wolk,Ramin Zand

DOI: https://doi.org/10.3389/fcvm.2021.649922

IF: 3.6

2021-03-29

Frontiers in Cardiovascular Medicine

Abstract:Since the early days of the pandemic, there have been several reports of cerebrovascular complications during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Numerous studies proposed a role for SARS-CoV-2 in igniting stroke. In this review, we focused on the pathoetiology of stroke among the infected patients. We pictured the results of the SARS-CoV-2 invasion to the central nervous system (CNS) via neuronal and hematogenous routes, in addition to viral infection in peripheral tissues with extensive crosstalk with the CNS. SARS-CoV-2 infection results in pro-inflammatory cytokine and chemokine release and activation of the immune system, COVID-19-associated coagulopathy, endotheliitis and vasculitis, hypoxia, imbalance in the renin-angiotensin system, and cardiovascular complications that all may lead to the incidence of stroke. Critically ill patients, those with pre-existing comorbidities and patients taking certain medications, such as drugs with elevated risk for arrhythmia or thrombophilia, are more susceptible to a stroke after SARS-CoV-2 infection. By providing a pictorial narrative review, we illustrated these associations in detail to broaden the scope of our understanding of stroke in SARS-CoV-2-infected patients. We also discussed the role of antiplatelets and anticoagulants for stroke prevention and the need for a personalized approach among patients with SARS-CoV-2 infection.

cardiac & cardiovascular systems
Impact of the COVID-19 Pandemic on Acute Ischemic Stroke Presentation, Treatment, and Outcomes

Timothy G. White,Gabriela Martinez,Jason Wang,Michele Gribko,Artem Boltyenkov,Rohan Arora,Jeffrey M. Katz,Henry H. Woo,Pina C. Sanelli

DOI: https://doi.org/10.1155/2021/8653396

2021-07-29

Stroke Research and Treatment

Abstract:Introduction. The World Health Organization declared COVID-19 a global pandemic last year. While a clear impact of COVID-19 on the declining stroke volume has been reported, its overall impact on stroke presentation and clinical outcomes has not been established. The purpose of this study was to assess the impact of COVID-19 on acute ischemic stroke volume, presentation, treatment, and outcomes at comprehensive stroke centers. Methods. A retrospective review of patients with a discharge diagnosis of acute ischemic stroke from the Get With The Guidelines database was performed from January 1, 2019, to July 1, 2020. The following time periods were defined: Pre-COVID (January/February), Peak-COVID (March/April), and Post-COVID (May/June). Bivariate analyses were performed comparing the 2020 and 2019 time periods to determine differences in stroke volume, presentation, treatment, and outcomes. Results. Stroke volumes were significantly lower during the Peak-COVID period in 2020 compared to that in 2019, with an absolute decline of 49.5% ( P < 0.001 ). Patients were more likely to present after 24 hours from last known well during the 2020 Peak-COVID period ( P = 0.03 ). However, there was not a significant difference in the rate of treatment with either the tissue plasminogen activator (tPA) or mechanical thrombectomy during the Peak-COVID period. Interestingly, relative treatment rates increased during the 2020 Post-COVID period to 11.4% ( P = 0.01 ). Conclusions. The overall ischemic stroke volume decreased during the pandemic, and patients had a tendency to present later, beyond eligible treatment windows. However, rates of treatment, patient demographics, and stroke outcomes did not significantly change when compared to the prior year.
Pharmacological concentrations of follicle-stimulating hormone and testosterone improve the efficacy of in vitro germ cell differentiation in men with maturation arrest.

J. Tesarik,Peter B. Nagy,R. Abdelmassih,E. Greco,C. Mendoza

DOI: https://doi.org/10.1016/S0015-0282(01)02969-7

IF: 6.7

2002-02-01

Fertility and Sterility

Abstract:
Outcomes of COVID-19 Complications and their Possibilities as Potential Triggers of Stroke

Urvish Patel,Preeti Malik,Deep Mehta,Priyanka Rajput,Mashu Shrivastava,Madiha Naveed,Eseosa Urhoghide,Mehwish Martin,Shamima Somi,Richa Jaiswal,Achint Patel,Avantika Israni,Jagmeet Singh,Asim Kichloo,Shamik Shah,Abhishek Lunagariya

DOI: https://doi.org/10.1016/j.jstrokecerebrovasdis.2021.105805

Abstract:Introduction: There is limited literature on coronavirus disease 2019 (COVID -19) complications such as thromboembolism, cardiac complications etc. as possible trigger for stroke. Hence, we aim to evaluate the prevalence and outcomes of COVID-19 related cardiovascular complications and secondary infection and their possibility as potential triggers for the stroke. Methods: Data from observational studies describing the complications [acute cardiac injury (ACI), cardiac arrhythmias (CA), disseminated intravascular coagulation (DIC), septic shock, secondary infection] and outcomes of COVID-19 hospitalized patients from December 1, 2019 to June 30, 2020, were extracted following PRISMA guidelines. Adverse outcomes defined as intensive care units, oxygen saturation less than 90%, invasive mechanical ventilation, severe disease, and in-hospital mortality. The odds ratio and 95% confidence interval were obtained, and forest plots were created using random-effects models. A short review of these complications as triggers of stroke was conducted. Results: 16 studies with 3480 confirmed COVID-19 patients, prevalence of ACI [38%vs5.9%], CA [26%vs5.3%], DIC [4%vs0.74%], septic shock [18%vs0.36%], and infection [30%vs12.5%] was higher among patients with poor outcomes. In meta-analysis, ACI [aOR:9.93(95%CI:3.95-25.00], CA [7.52(3.29-17.18)], DIC [7.36(1.24-43.73)], septic shock [30.12(7.56-120.10)], and infection [10.41(4.47-24.27)] had higher odds of adverse outcomes. Patients hospitalized with acute ischemic stroke and intracerebral hemorrhage, had complications like pulmonary embolism, venous thromboembolism, DIC, etc. and had poor outcomes CONCLUSION: The complications like acute cardiac injury, cardiac arrhythmias, DIC, septic shock, and secondary infection had poor outcomes. Patients with stroke were having history of these complications. Long term monitoring is required in such patients to prevent stroke and mitigate adverse outcomes.
The influence of COVID-19 on short-term mortality in acute ischemic stroke: A systematic review and meta-analysis

Yi-dong Xue,Ying-ying Zheng,Chan Cao,Qiang Shi

DOI: https://doi.org/10.1097/md.0000000000039761

IF: 1.6

2024-09-29

Medicine

Abstract:Since the outbreak of coronavirus disease 2019 (COVID-19), >600 million people have had confirmed cases of COVID-19 with >6.6 million deaths worldwide. The morbidity and mortality of COVID-19 and its complications have become a public health crisis. [ 1–4 ] Global are still being made to understand the risks, complications, and outcomes of SARS-CoV-2 infection so that people can make timely and informed decisions in the face of emergency situations. [ 2 , 5 , 6 ]

medicine, general & internal
Effect of COVID-19 on Acute Ischemic Stroke Severity and Mortality in 2020: Results From the 2020 National Inpatient Sample

Adam de HavenonLily W. ZhouShadi YaghiJennifer A. FronteraKevin N. ShethDepartment of Neurology,Yale University,New Haven,CT (A.d.H.,K.N.S.).Department of Neurology,The University of British Columbia,Vancouver,Canada (L.W.Z.).Department of Neurology,Brown University,Providence,RI (S.Y.).Department of Neurology,New York University,NY (J.A.F.).

DOI: https://doi.org/10.1161/STROKEAHA.122.041929

IF: 10.17

2023-04-07

Stroke

Abstract:Stroke, Ahead of Print. Background:There is a paucity of nationally representative data regarding the impact of COVID-19 on acute ischemic stroke (AIS) outcome.Methods:We created a cross-sectional cohort of nationally weighted National Inpatient Sample nonelective hospital discharges aged ≥18 years with a diagnosis of ischemic stroke from 2016 to 2020. The outcome was in-hospital mortality and exposure was COVID-19 status. To understand the effect of COVID-19 on AIS severity, we report National Institutes of Health Stroke Scale by exposure status. In a final analysis, we used a nationally weighted logistic regression and marginal effects to compare April to December 2020 to the same period in 2019 to understand how the pandemic modified the effect of race and ethnicity and median household income on in-hospital AIS mortality.Results:We observed significantly higher AIS mortality in 2020 than prior years (2020 versus 2016-19, 7.3% versus 6.3%,P<0.001) and higher National Institutes of Health Stroke Scale in those with COVID-19 than those without (mean: 9.7±9.1 versus 6.6±7.4,P<0.001), but patients with AIS without COVID in 2020 had only marginally higher mortality (2020 versus 2016–2019, 6.6% versus 6.3%,P=0.001). Comparing April to December 2020 to 2019, the adjusted risk of in-hospital AIS mortality was most notably increased in Hispanics (2020 versus 2019: 9.2% versus 5.8%,P<0.001) and the lowest quartile of income (2020 versus 2019: 8.0% versus 6.0%,P<0.001).Conclusions:In-hospital stroke mortality increased in 2020 in the United States because of comorbid AIS and COVID-19, which had higher stroke severity. The increase in AIS mortality during April-December 2020 was significantly more pronounced in Hispanics and those in the lowest quartile of household income.

peripheral vascular disease,clinical neurology

Reconnaissance Soil Geochemical Survey of Gibraltar

Gonorrhea in the female.

Hemorrhagic and ischemic stroke in patients with coronavirus disease 2019: incidence, risk factors, and pathogenesis - a systematic review and meta-analysis

Incidence of Stroke in Randomized Trials of COVID-19 Therapeutics: A Systematic Review and Meta-Analysis.

Abstract P81: SARS-CoV-2 and Stroke Characteristics a Report From the Multinational COVID-19 Stroke Study Group

Acute Ischemic Stroke and COVID-19: An Analysis of 27 676 Patients.

COVID-19 and cerebrovascular diseases: a comprehensive overview

Influence of ascending versus descending balloon counterpulsation on bypass graft blood flow.

Risk of stroke in hospitalized SARS-CoV-2 infected patients: A multinational study

Abstract P88: Risk of Stroke in Hospitalized SARS-Cov-2 Infected Patients a Multinational Population-Based Study

An Electron Optical Survey of Iron Oxide o Films Produced in H 20 , 1 . 5 % LiOH , and ULiOT / EDTA ( pH 11 ) Solutions at 316 0 C

Bihemispheric ischemic strokes in patients with COVID-19

Efficacy and safety of recanalization therapy for acute ischemic stroke with COVID-19: A systematic review and meta-analysis

Association between SARS-CoV-2 and Stroke: Perspectives from a metaumbrella-review.

Risk of ischemic stroke in patients recovered from COVID-19 infection: A systematic review and meta-analysis

Stroke in SARS-CoV-2 Infection: A Pictorial Overview of the Pathoetiology

Impact of the COVID-19 Pandemic on Acute Ischemic Stroke Presentation, Treatment, and Outcomes

Pharmacological concentrations of follicle-stimulating hormone and testosterone improve the efficacy of in vitro germ cell differentiation in men with maturation arrest.

Outcomes of COVID-19 Complications and their Possibilities as Potential Triggers of Stroke

The influence of COVID-19 on short-term mortality in acute ischemic stroke: A systematic review and meta-analysis

Effect of COVID-19 on Acute Ischemic Stroke Severity and Mortality in 2020: Results From the 2020 National Inpatient Sample